Physician profile
Krishna Patel
NPI 1790131753
$16,158.42
in general payments reported to CMS, 2019-2025
44 companies · $6,112 in 2025
The $6,112 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,176 · 2020: $338 · 2021: $321 · 2022: $1,845 · 2023: $3,263 · 2024: $3,104 · 2025: $6,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $1,458 · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,706.42 |
| Travel and Lodging | $1,458.48 |
| Education | $313.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,161.81 | 2019-2025 | |
| Axogen | $2,055.07 | 2025 | |
| Janssen Biotech, INC. | $1,604.23 | 2022-2025 | Tremfya, Simponi, Stelara |
| Amgen INC. | $1,434.79 | 2020-2025 | Otezla, Otezla |
| Lilly USA, LLC | $1,296.11 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $1,133.31 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,130.20 | 2019-2025 | |
| Galderma Laboratories, L.P. | $821.26 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Integra Lifesciences Corporation | $527.51 | 2022-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Incyte Corporation | $389.58 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $388.12 | 2021-2025 | Ilumya, Winlevi |
| Leo Pharma INC. | $359.56 | 2022-2025 | Adbry |
| Celgene Corporation | $282.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $282.42 | 2023-2025 | |
| Ucb, INC. | $224.91 | 2024-2025 | Bimzelx |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $193.65 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $146.71 | 2023-2025 | Zoryve |
| Fresenius Kabi USA, LLC | $145.71 | 2023-2024 | Idacio |
| Abbott Laboratories | $144.10 | 2022 | |
| Kerecis Limited | $139.89 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Merz North America, INC. | $131.96 | 2022 | |
| Smith+Nephew, INC. | $112.10 | 2020-2025 | Grafix Pl |
| E.R. Squibb & Sons, L.L.C. | $109.12 | 2022-2024 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $98.61 | 2019 | |
| Janssen Scientific Affairs, LLC | $96.18 | 2022 | |
| Dermavant Sciences, INC. | $84.71 | 2023-2024 | Vtama |
| Pfizer INC. | $79.20 | 2023-2024 | |
| Ardelyx, INC. | $70.94 | 2024 | Ibsrela |
| Epi Health, LLC | $52.45 | 2022 | |
| Eli Lilly and Company | $52.21 | 2025 | Omvoh |
| Verrica Pharmaceuticals INC. | $43.92 | 2025 | Ycanth |
| Organon LLC | $42.44 | 2025 | Vtama |
| Cipher Pharmaceuticals US LLC | $39.94 | 2025 | Natroba, Spinosad |
| Strata Skin Sciences, INC. | $39.05 | 2024-2025 | Xtrac |
| Takeda Pharmaceuticals U.S.A., INC. | $38.94 | 2025 | Entyvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.16 | 2022-2025 | Spevigo |
| Biofrontera INC. | $37.52 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Botanix Sb INC | $30.84 | 2025 | Sofdra |
| Celltrion USA INC. | $23.58 | 2024 | Zymfentra |
| Polynovo North America LLC | $18.14 | 2024 | Novosorb Btm |
| Iovance Biotherapeutics, INC. | $15.56 | 2025 | Amtagvi |
| Helsinn Therapeutics (U.S.), INC. | $15.30 | 2023 | Valchlor |
| Journey Medical Corporation | $14.69 | 2022 | |
| Almirall LLC | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.